Validation of uHear™ as a Screening Tool to Detect Hearing Impairment in Older Cancer Patients Within a Comprehensive Geriatric Assessment - BIS

General Hospital Groeninge1 site in 1 country45 target enrollmentJanuary 2016

ConditionsOlder Cancer Patients

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Older Cancer Patients
Sponsor: General Hospital Groeninge
Enrollment: 45
Locations: 1
Primary Endpoint: Validation of uHear™ with its new scoring method as a screening tool to detect hearing loss in older cancer patients
Status: Completed
Last Updated: 8 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The aim of this study is to validate uHear™, an iOS-based tool, as a screening tool to detect significant hearing impairment as part of a comprehensive geriatric assessment in patients aged 70 years and older. The pass or fail screening cut-off is defined as having two or more consecutive hearing grades starting from the moderate-severe threshold zone ranging from 0.5 - 2.0 kHz.

Registry

clinicaltrials.gov

Start Date

January 2016

End Date

September 2016

Last Updated

8 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

General Hospital Groeninge

Responsible Party

Principal Investigator

Dr. Philip Debruyne

Medical Oncologist

General Hospital Groeninge

Eligibility Criteria

Inclusion Criteria

•Patients should have reached the age of 70 or more at enrolment
•Histologically confirmed diagnosis of solid cancer or hematologic malignancy. All stages of cancer are eligible
•Patients should be fluent in Dutch or French
•Patients must receive their primary oncology care in the participating hospital
•Patients should be cognitively capable of performing the audiology assessment
•Patients should be scheduled to receive a CGA
•Patients should have signed informed consent

Exclusion Criteria

•Patients who do not match the above inclusion criteria
•Patients presenting with clinically diagnosed Meniere's disease, retrocochlear hearing loss, autoimmune inner ear disease, fluctuating hearing loss or a history of sudden sensory neural hearing loss
•Patients who already have a hearing aid or a previously diagnosed hearing loss